GH Research PLC (NASDAQ:GHRS - Get Free Report) fell 0.1% during mid-day trading on Tuesday . The company traded as low as $7.92 and last traded at $8.05. 20,530 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 79,945 shares. The stock had previously closed at $8.06.
Analyst Upgrades and Downgrades
Several research analysts recently commented on GHRS shares. JMP Securities restated a "market outperform" rating and set a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th.
View Our Latest Analysis on GHRS
GH Research Stock Performance
The firm has a fifty day moving average price of $8.20 and a 200 day moving average price of $10.59. The company has a market cap of $421.43 million, a price-to-earnings ratio of -13.06 and a beta of 0.79.
GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. On average, analysts expect that GH Research PLC will post -0.89 EPS for the current fiscal year.
Institutional Trading of GH Research
A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP grew its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,966,726 shares of the company's stock after acquiring an additional 656,163 shares during the period. GH Research accounts for 16.7% of Lynx1 Capital Management LP's holdings, making the stock its 3rd largest position. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
